Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than F-fluorodeoxyglucose ([F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, F-O-(2-fluoroethyl)-L-tyrosine ([F]F-FET), F-Fluorothymidine ([F]F-FLT) and C-Methionine ([C]C-MET). [F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression. In addition, models built using clinical parameters and [F]F-FET-PET-derived radiomics features showed acceptable results for survival stratification of glioblastoma patients. [F]F-FLT-PET-based characteristics also showed potential in evaluating glioma patients, correlating with Ki-67 and patient prognosis. AI-based PET-volumetry using this radiotracer as a proliferation marker also revealed promising preliminary results in terms of guide-targeting bone marrow-preserving adaptive radiation therapy. Similar to [F]F-FET, the other amino acid tracer which reflects cellular proliferation, [C]C-MET, has also shown acceptable performance in predicting tumor grade, distinguishing brain tumor recurrence from radiation necrosis, and treatment monitoring by PET-derived radiomics models. In addition, PET-derived radiomics features of various radiotracers such as [F]F-DOPA, [F]F-FACBC, [F]F-NaF, [Ga]Ga-CXCR-4 and [F]F-FMISO may also provide useful information for tumor characterization and predict of disease outcome. In conclusion, AI using tracers beyond [F]F-FDG could improve the diagnostic performance of PET-imaging for specific indications and help clinicians in their daily routine by providing features that are often not detectable by the naked eye.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.semnuclmed.2024.01.002 | DOI Listing |
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, University of Bern, Bern, Switzerland.
Purpose: Radiomics has revolutionized clinical research by enabling objective measurements of imaging-derived biomarkers. However, the true potential of radiomics necessitates a comprehensive understanding of the biological basis of extracted features to serve as a clinical decision support. In this work, we propose an end-to-end framework for the in silico simulation of [F]FLT PET imaging process in Pancreatic Ductal Adenocarcinoma, accounting for the biological characterization of tissues (including perfusion and fibrosis) on tracer delivery.
View Article and Find Full Text PDFClin Radiol
October 2024
Izmir Katip Celebi University, Ataturk Training and Research Hospital, Department of Nuclear Medicine, Basin Sitesi, 35360, Izmir, Turkiye. Electronic address:
Aim: The aim of this study is to investigate the importance of the quantitative parameters of the tumoral and peritumoral regions in prediction of pathological subtypes and 1-year survival in patients with esophageal carcinoma.
Materials And Methods: A total of 103 patients with esophageal squamous cell carcinoma (SCC) and adenocarcinoma (AC) and in whom fluorodeoxyglucose positron emission tomography/computerized tomography (F-FDG PET/CT) was performed were included in the study. One-year progression-free survival (PFS) and overall survival times of all patients were noted.
BMC Cancer
October 2024
Department of PET/CT, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Background: Sentinel lymph node (SLN) biopsy (SLNB) is considered the gold standard for detecting SLN metastases in patients with invasive ductal breast cancer (IDC). However, SLNB is invasive and associated with several complications. Thus, this study aimed to evaluate the diagnostic performance of a non-invasive radiomics analysis utilizing 2-deoxy-2-[F]fluoro-d-glucose positron emission tomography/computed tomography (F-FDG-PET/CT) for assessing SLN metastasis in IDC patients.
View Article and Find Full Text PDFDiagnostics (Basel)
June 2024
University Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, ON M5G 2N2, Canada.
We aimed to determine if clinical parameters and radiomics combined with sarcopenia status derived from baseline F-FDG-PET/CT could predict developing metastatic disease and overall survival (OS) in gastroesophageal cancer (GEC). Patients referred for primary staging who underwent F-FDG-PET/CT from 2008 to 2019 were evaluated retrospectively. Overall, 243 GEC patients (mean age = 64) were enrolled.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
October 2024
Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675, München, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!